Exploring the gut microbiome in IBS patients
Generating a Stool Microbiome-based Diagnostic for IBS (Irritable Bowel Syndrome) Patients in Low-FODMAP Treated and Untreated IBS Patients
This study is testing how a low FODMAP diet affects the gut bacteria and symptoms of people with Irritable Bowel Syndrome (IBS).
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 200 (estimated) |
| Ages | 18 Years to 70 Years |
| Sex | All |
| Sponsor | Weizmann Institute of Science Academic / other |
| Locations | 1 site (Rehovot, Israel) |
| Trial ID | NCT05972317 on ClinicalTrials.gov |
What this trial studies
This study investigates the differences in the stool microbiome between treated and untreated patients with Irritable Bowel Syndrome (IBS). It focuses on understanding how dietary factors influence gut microbiome composition and the production of metabolites that may contribute to IBS symptoms. By analyzing the specific small molecules and bacteria involved, the study aims to uncover the mechanisms behind IBS and its flares. Participants will follow a low FODMAP dietary regimen to assess its impact on their microbiome and symptoms.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18-70 who have been diagnosed with IBS.
Not a fit: Patients with chronic diseases, psychiatric disorders, or those who have recently undergone cancer treatment may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to personalized dietary recommendations that improve the management of IBS symptoms.
How similar studies have performed: Other studies have shown promising results in understanding the gut microbiome's role in IBS, suggesting that this approach could yield valuable insights.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Male and Female * Age - 18-70 Exclusion Criteria: * Consumption of antibiotics 2 months prior to the first day of the experiment. * Consumption of probiotic supplements 1 month prior to the first day of the experiment. * Type 1 or type 2 diabetes diagnosis. * Pregnancy, fertility treatments, breastfeeding 3 months prior to the first day of the study. * Chronic disease - to the discretion of the study doctor. * Cancer and recent anticancer treatment. * Psychiatric disorders - to the discretion of the study doctor. * IBD (inflammatory bowel diseases). * Alcohol or substance abuse. * BMI \> 35.
Where this trial is running
Rehovot, Israel
- Weizmann institute of science — Rehovot, Israel, Israel (Recruiting)
Study contacts
- Principal investigator: Eran Elinav, Prof — Weizmann Institute of Science
- Study coordinator: Yotam Cohen
- Email: Yotam.cohen@weizmann.ac.il
- Phone: +97289529173
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.